TCGA-CR-7364-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.460
- ANDROGEN_RESPONSE+0.360
- ESTROGEN_RESPONSE_EARLY+0.270
- UV_RESPONSE_DN+0.270
- ESTROGEN_RESPONSE_LATE+0.240
- XENOBIOTIC_METABOLISM+0.240
- HEDGEHOG_SIGNALING+0.230
- SPERMATOGENESIS+0.210
- BILE_ACID_METABOLISM+0.200
- KRAS_SIGNALING_DN+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- MYC_TARGETS_V2-0.380
- INTERFERON_GAMMA_RESPONSE-0.350
- E2F_TARGETS-0.320
- MYOGENESIS-0.280
- DNA_REPAIR-0.270
- MYC_TARGETS_V1-0.270
- OXIDATIVE_PHOSPHORYLATION-0.260
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598079 | fetal | fetal | 0.739 |
| 2 | SRR8613737 | — | F | 0.702 |
| 3 | TCGA-D8-A1X8-01A-11R-A14M-07 | — | B | 0.699 |
| 4 | TCGA-A2-A3KD-01A-12R-A213-07 | — | A | 0.692 |
| 5 | TCGA-D8-A1JF-01A-11R-A13Q-07 | — | F | 0.684 |
| 6 | TCGA-CR-7371-01A-11R-2016-07 | — | — | 0.681 |
| 7 | fb5d10ba-36f3-4236-b8fd-7c057db51039 | — | — | 0.679 |
| 8 | MNG622 | — | — | 0.676 |
| 9 | MNG1171 | — | — | 0.670 |
| 10 | BS_GV3NZ9QD | EPN | EPN Tumor | 0.660 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |